Veeva Systems (VEEV) and BioMarin Pharmaceutical (BMRN) announced a long-term enterprise agreement that builds upon their long-standing relationship. The expanded partnership will help BioMarin increase speed, agility, operational efficiency, and optimize the healthcare professional and patient experience by further leveraging and providing strategic input into Veeva’s software, data, services, and consulting products.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VEEV:
- High Valuation and CRM Transition Risks Drive Sell Rating on Veeva Systems
- Closing Bell Movers: Aeva surges after announcing Nvidia integration
- Veeva announces $2B share repurchase program
- Veeva Systems Announces First-Ever $2 Billion Share Buyback
- Veeva authorized to purchase up to $2B of shares of Class A stock